Amphetamine-Related Emergency Department Visits in Ontario, Canada, 2003-2020

Abstract

Objectives Despite unregulated amphetamine use increasing, there are limited data on related emergency department (ED) visits in Canada. Our primary objective was to examine trends in amphetamine-related ED visits over time in Ontario, including by age and sex. Secondary objectives were to examine whether patient characteristics were associated with ED revisit within 6 months. Methods Using administrative claims and census data, we calculated annual patient- and encounter-based rates of amphetamine-related ED visits from 2003 to 2020 among individuals 18+ years of age. We also performed a retrospective cohort study of individuals with amphetamine-related ED visits between 2019 and 2020 to determine whether select factors were associated with ED revisit within 6 months. Multivariable logistic regression modelling was used to measure associations. Results The population-based rate of amphetamine-related ED visits increased nearly 15-fold between 2003 (1.9/100,000 Ontarians) and 2020 (27.9/100,000 Ontarians). Seventy-five percent of individuals returned to the ED for any reason within 6 months. Psychosis and use of other substances were both independently associated with ED revisit for any reason within 6 months (psychosis: AOR = 1.54, 95% CI = 1.30–1.83; other substances: AOR = 1.84, 95% CI = 1.57–2.15), whereas having a primary care physician was negatively associated with ED revisit (AOR = 0.77, 95% CI = 0.60–0.98). Conclusions Increasing rates of amphetamine-related ED visits in Ontario are cause for concern. Diagnoses of psychosis and the use of other substances may serve to identify individuals who are most likely to benefit from both primary and substance-specific care.

Perceptions of stigma among people with lived experience of methamphetamine use within the hospital setting: qualitative point-in-time interviews and thematic analyses of experiences

“…In British Columbia, the presence of methamphetamine in drug toxicity-related deaths increased from 20.7% in 2012 to 43% in 2022 ( 6 ), and methamphetamine was involved in 52% of apparent stimulant toxicity deaths across Canada between January and September 2022 ( 7 ). In Ontario, there was an increase of more than 200% in population-based emergency department visits related to amphetamines between 2015 and 2020 ( 8 ).…”

Biomimetic electrospun PVDF/self-assembling peptide piezoelectric scaffolds for neural stem cell transplantation in neural tissue engineering

“…Spinal cord injuries (SCIs), the leading cause of irreversible paralysis, have a profound and devastating impact on the lives of more than 20 million people worldwide due to the limited capability to regenerate or replace neuronal tissue. 1 Previous studies in the field of neurobiology revealed that the deficiency of neuronal regeneration in the central nervous system (CNS) is not only because of the intrinsic lack of CNS axon regeneration ability but also because of extrinsic cell growth inhibition signals conferred by the CNS environment within the damaged tissue. 2 Thus, if neurons are provided with the correct set of biological and physical stimuli, regeneration of the damaged neuronal tissue should be favored.…”

Prescription psychostimulants for the treatment of amphetamine‐type stimulant use disorder: A systematic review and meta‐analysis of randomized placebo‐controlled trials

“…In the last decades, an ever-growing prevalence of people who use amphetamine-type stimulants (ATS) has been reported in various regions of the world [1][2][3]. According to the World Drug Report 2022, 34 million people used amphetamines in the year 2020 alone [2].…”